Aquatic Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Aquatic Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49M	Buy	+12,180	New	+$1.27M	0.05%	447
2026 Q1	–	Sell	-36,615	Closed	-$3.2M	–	1725
2025 Q4	$3.2M	Buy	+36,615	New	+$3M	0.09%	272
2025 Q3	–	Sell	-42,000	Closed	-$2.32M	–	1609
2025 Q2	$2.32M	Buy	42,000 +26,893	+178%	+$1.29M	0.05%	437
2025 Q1	$731K	Buy	+15,107	New	+$633K	0.02%	677
2024 Q2	–	Sell	-2,300	Closed	-$66.5K	–	1526
2024 Q1	$66.5K	Sell	2,300 -6,400	-74%	-$174K	﹤0.01%	992
2023 Q4	$199K	Buy	8,700 +200	+2%	+$3.5K	0.01%	848
2023 Q3	$142K	Buy	8,500 +7,400	+673%	+$144K	0.01%	756
2023 Q2	$30K	Buy	+1,100	New	+$27.5K	﹤0.01%	1073
2023 Q1	–	Sell	-22,300	Closed	-$243K	–	1665
2022 Q4	$243K	Buy	+22,300	New	+$188K	0.02%	698

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aquatic Capital Management's PTGX Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 12,180 shares worth $1.49M. The stake represents 0.05% of the portfolio and ranks #447 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in PTGX as recently as Q4 2025.

Aquatic Capital Management first reported a position in PTGX in Q4 2022 and has held it in 9 quarters since. The position peaked at $3.2M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Aquatic Capital Management held 12,180 shares of Protagonist Therapeutics worth $1.49M as of Q2 2026.
Protagonist Therapeutics was a new Aquatic Capital Management position in Q2 2026.
Protagonist Therapeutics made up 0.05% of Aquatic Capital Management's portfolio in Q2 2026, its #447 holding.
Aquatic Capital Management first reported a position in Protagonist Therapeutics in Q4 2022 and has held it in 9 quarters since.
Aquatic Capital Management's Protagonist Therapeutics position peaked at $3.2M in Q4 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.